Browsing Tag
rare disease drug development
1 post
Rezolute shares plunge after Phase 3 sunRIZE study fails to show significant benefit in congenital hyperinsulinism
Rezolute shares collapsed after its Phase 3 sunRIZE trial failed in congenital hyperinsulinism. Find out what went wrong and what it means for investors now.